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Introduction: Treatment for differentiated thyroid carcinoma (DTC) in pediatric patients is based
mainly on evidence from adult series due to lack of data from pediatric cohorts. Our objective was
to evaluate presentation, treatment-related complications, and long-term outcome in patients
with pediatric DTC in the Netherlands.
Patients and methods: In this nationwide study, presentation, complications and outcome of
patients with pediatric DTC (age at diagnosis18 years) treated in the Netherlands between 1970
and 2013 were assessed using medical records.
Results: We identified 170 patients. Overall survival was 99.4% after median follow-up of 13.5
(range 0.3–44.7) years. Extensive follow-up data were available for 105 patients (83.8% women),
treated in39hospitals.Medianageatdiagnosiswas15.6 (range5.8–18.9) years.At initialdiagnosis,
43.8% of the patients had cervical lymph node metastases; 13.3% had distant metastases. All
patients underwent total thyroidectomy. Radioiodine was administered to 97.1%, with a median
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cumulative activity of 5.66 (range 0.74–35.15) GBq. Lifelong postoperative complications (perma-
nent hypoparathyroidism and/or recurrent laryngeal nerve injury) were present in 32.4% of the
patients. At last known follow-up, 8.6% of the patients had persistent disease and 7.6% experi-
enced a recurrence. TSH suppression was not associated with recurrences (OR 2.00, 95% CI 0.78 to
5.17, P  0.152).
Conclusions: Survival of pediatric DTC is excellent. Therefore, minimizing treatment-related mor-
bidity takes major priority. Our study shows a frequent occurrence of lifelong postoperative com-
plications. Adverse effects may be reduced by centralization of care, which is crucial for children
with DTC.
Differentiated thyroid carcinoma (DTC), which com-prises papillary (PTC) and follicular thyroid carci-
noma (FTC), is a rare disease during childhood. Age-stan-
dardized incidence rates for children 0–4 years of age are
0.4per100.000, andup to1.5per100.000 for adolescents
aged 15–19 years (1). However, DTC is themost common
pediatric endocrine malignancy and its incidence is in-
creasing (1–3). The prognosis in children has been re-
ported to be excellent with 15-year survival rates 95%
(3). Due to sparse pediatric data, however, thyroid cancer
care for pediatric patients is based predominantly on ev-
idence from adult series. This year, the American Thyroid
Association (ATA) published their first guidelines for chil-
drenwithDTC, thereby providing a thoroughoverviewof
the available literature (4).
The initial treatment for children with DTC generally
consists of a (near) total thyroidectomy with or without
lymph node dissection, although for patients with mini-
mally invasive FTC 4 cm and lacking other adverse risk
factors, a less aggressive treatment has recently been rec-
ommended (4, 5).Complication rates of thyroid surgery in
children have been reported to be higher than those in
adults (6). In most cases, surgery is followed by ablation
therapywith radioactive iodine (131-I) to destroy residual
tumor foci and to facilitate disease monitoring by fol-
low-up scans and measurement of serum thyroglobulin
(Tg). However, nowadays 131-I administration often de-
pends on risk stratification (4, 5). Pediatric patients with
residual tumor and/or metastases are generally treated by
cyclic 131-I administrations, with the activity of 131-I be-
ing a matter of discussion (7). To decrease the risk of re-
current disease, TSH suppressive therapy with thyroid
hormone has for decades been considered necessary dur-
ing follow-up, but its use is currently tempered in patients
showing no evidence of disease (4, 8–10).
Awareness regarding treatment-related morbidity is
growing. However, long-term follow-up data, especially
long-term data on morbidity, of children not exposed to
the post-Chernobyl fallout are limited. Past studies in chil-
dren  18 years at diagnosis have frequently been ham-
pered by short follow-up, small patient series, series in-
cluding patients with benign conditions, or treatment
regimens not representative of current practice (eg, includ-
ing external beam radiotherapy) (11–15). Therefore, de-
tailed insight into relevant clinical parameters of DTC in
children is necessary to improve evidence-based treatment
and follow-up strategies. The objective of this nationwide
studywas to evaluate thepresentation, complications, and
long-term outcome in patients with pediatric DTC in the
Netherlands.
Patients and Methods
Study design and population
In this nationwide retrospective cohort study, children 18
years diagnosed with PTC or FTC between January 1970 and
December 2013 and treated in the Netherlands were eligible for
inclusion. The Dutch population is considered to be iodine-suf-
ficient with virtually no exposure to the post-Chernobyl radio-
iodine fallout (16). To create a national cohort with coverage as
high as reasonably feasible, patients were traced using data from
the Netherlands Cancer Registry (1989–2013) and from hospi-
tal registries of theUniversityMedicalCenters (UMCs), inwhich
patientswere generally registered from1970onwards.Mortality
data were obtained from electronic hospital patient information
systems. For patients lost to follow-up, linkagewith the database
of the Central Bureau for Genealogy in the Netherlands was
performed to identify deceased subjects. The Institutional Re-
view Board of the University Medical Center Groningen ap-
proved the study. Informed consent was given by the patients
and/or by their parents, for minors.
Data collection
Medical history, diagnosis, and treatment details were ob-
tained from patients’ medical records. Histopathological data
were obtained from the original pathology reports. As the TNM
Classification of Malignant Tumors was changed several times
within the period covered by this study, tumor stage was (re-
)classified according to the seventh edition of the TNM classi-
fication to facilitate comparison of the tumors (17). Data re-
garding 131-I administrations (number and activities of 131-I,
and results of scans, both therapeutic and imaging) were col-
lected from reports of the Departments of NuclearMedicine. To
calculate the cumulative administered 131-I activity, only abla-
tive and therapeutic 131-I administrations were taken into ac-
count. TSHvalueswere collected from the laboratory reports. In
case of missing data, medical correspondence and the general
practitioner were consulted.
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Study definitions
Date of diagnosis was defined as the date of histological con-
firmation of thyroid carcinoma. Follow-up time was calculated
from the date of diagnosis until the date of the patient’s last
known assessment or the date of the patient’s death. Age at di-
agnosiswas classified into 3 groups: age 0–10, 11–14 and 15–18
years. Transient and permanent hypoparathyroidism were de-
finedby theuseof calciumorvitaminDsupplements for less than
6months, and more than 6months after thyroidectomy, respec-
tively, or if these conditions were reported as such in themedical
records. Recurrent laryngeal nerve (RLN) injury was defined as
injurymentioned in EarNose and Throat report or, if this report
was not available, in other medical records. Injury due to en-
casement by tumorwas also defined as recurrent laryngeal nerve
injury. Remission was defined as the absence of clinical, scinti-
graphical, or radiologic evidence of disease and undetectable
serumTg under TSH suppressive therapy for at least 1 year after
the last 131-I therapy. Persistent disease was defined as the ab-
sence of remission.Recurrent diseasewasdefined as histological,
cytological, radiological, orbiochemical evidenceofdisease after
remission. Patients were classified according to risk of recur-
rence: low (T1-T2,N0,M0), intermediate (anyT3orN1 tumor),
or high (any T4 or M1 tumor).
Statistical analysis
Groups were compared using 2 or Fisher’s exact tests (if
conditions for 2 test were not met) in the case of categorical
variables. Mann-Whitney U and Kruskal-Wallis tests were per-
formed for non-normally distributed continuous variables.
Missing or unknown values were excluded from statistical test-
ing. The TSH level for each year of follow-up was expressed as
the geometricmean of the observedTSHvalues during that year.
TSH values that were obtained before thyroidectomy until 12
weeks postoperatively were excluded, as well as TSH values ob-
tained 6 weeks before until 12 weeks after thyroid hormone
withdrawal or use of recombinant human (rh) TSH. The TSH
level during the entire follow-up was defined as the geometric
mean of the calculated TSH levels per year (18). Logistic regres-
sion analyses were performed to explore the associations be-
tween TSH level and recurrent disease, and between the occur-
rence of surgical complications and hospital volume, time of
surgery, and age group. Regarding the association between TSH
and recurrent disease, TSH was entered continuously in the
crude model, followed by adjustment for risk classification. The
associations between surgical complications and hospital vol-
ume, time of surgery, and age group were explored in a crude
model, followedbyadjustment forT-stage (T1-T2vsT3-T4) and
the performance of lymph node dissection. Patients surgically
treated in 1 hospital were excluded from the analysis, as it was
retrospectively unclear in which hospital the complication oc-
curred. All tests were two-sided. A P value of  0.05 was con-
sidered significant. IBM SPSS Statistics version 22 (IBM, Ar-
monk, NY, USA) was used for statistical analyses.
Results
As shown in the study flowchart (Figure 1), 170 patients
with pediatric DTC were identified. One patient with fa-
milial adenomatous polyposis died at the age of 20 years
due to complications of a colon carcinoma. He had been
diagnosed 5 years earlier with PTC with lung metastases.
Overall survival was 99.4% after a median follow-up of
13.5 (range 0.3–44.7) years. Of the 169 survivors, 105
(62.1%) gave informed consent and were included in this
study. The patients from whom no informed consent was
obtained were more often male (29.7% vs. 16.2%, P 
.038), and more often had distant metastases (P  .031)
and a longer follow-up time (median 18.1 (range 0.3–
40.4) years vs. 11.7 (range 1.1–44.7) years, P  .043,
Supplemental Table 1).
Baseline characteristics
Baseline characteristics are provided in Table 1. The
female: male ratiowas 5.2:1.Median age at diagnosis was
15.6 (range5.8–18.9) years. PTCwasdiagnosed in81.0%
of the patients; the remaining 19.0% had FTC. At initial
diagnosis, histologically confirmed cervical lymph node
metastases were found in 46 (43.8%) patients and distant
metastases in 14 (13.3%) patients. Of these, 11 patients
had lung metastases, 1 patient with FTC had a metastasis
in the seventh thoracic vertebra and 2 patients with PTC
andFTC, respectively, hadboth lungandbonemetastases.
Figure 1. Study flowchart, showing final number of included patients
and reasons for nonparticipation of eligible patients.
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Pathological features and TNM stage did not differ be-
tween the 3 age groups.
Medical history
Four (3.8%) patients developed DTC as a second ma-
lignant neoplasm (SMN); 2 of them had been treated with
cranial radiotherapy (Supplemental Table 2). One patient
with a neuroblastoma had been treated with 131-I-meta-
iodobenzylguanidine (previously reported (19)). The
fourth patient had been treated for Langerhans cell histi-
ocytosis. She did not receive radiotherapy. Two (1.9%)
patients developed PTC after radiotherapy directed to the
neck for benign conditions.
Surgical treatment
Total thyroidectomy was performed in all patients. In
65 (61.9%) patients the total thyroidectomy was per-
formed as a single procedure. In the remaining 40 (38.1%)
patients a diagnostic hemithyroidectomy was performed,
followed by a completion thyroidectomy. The mean time
span between both procedures was 31.5 (range 2–210)
days.
Lymph node dissectionwas performed as part of initial
therapy in 46 (43.8%) patients, of whom 40 (87.0%) had
histologically proven lymph node metastases. In 10
(9.5%) patients the central compartment (level VI) was
dissected; in 36 (34.4%) patients a lateral lymph node
dissection was performed, including other levels (II-V) on
one or both sides of the neck (Table 1). In 6 patients not
initially treated with a lymph node dissection, positive
lymph nodes were found during histopathological exam-
ination. Central compartment dissection alone was per-
formedmore frequently in childrenaged0–10years,while
in older children lateral levels weremore often included in
the lymph node dissection (P  .045, Table 1).
Throughout the entire study period, patients were sur-
gically treated in 39 hospitals, including 9 UMCs and 30
general hospitals. During this period, in our cohort, the
median number of surgical procedures (hemi- or total thy-
Table 1. Baseline characteristics
Variable All patients (n  105) 0–10 yr (n  10) 11–14 yr (n  34) 15–18 yr (n  61)
P
valuea
Sex, no. (%)
Male 17 (16.2) 5 (50.0) 6 (17.6) 6 (9.8) 0.006
Female 88 (83.8) 5 (50.0) 28 (82.4) 55 (90.2)
Age at diagnosis, years
Median (range) 15.6 (5.8–18.9) 9.5 (5.8–10.8) 13.0 (11.1–14.8) 17.1 (15.3–18.9) -
Histology, no. (%)
Papillary 85 (81.0) 9 (90.0) 25 (73.5) 51 (83.6) 0.363
Follicular 20 (19.0) 1 (10.0) 9 (26.5) 10 (16.4)
Primary tumor size, cm
Median (range) 2.5 (0.3–9.0) 1.4 (0.8–5.0) 2.9 (1.0–5.5) 2.5 (0.3–9.0) 0.193
Localization, no. (%)
Unilateral 67 (63.8) 5 (50.0) 23 (67.7) 39 (63.9) 0.493
Bilateral 28 (26.7) 3 (30.0) 9 (26.5) 16 (26.2)
Otherb
Isthmus 3 (2.9) 1 (10.0) 0 (0.0) 2 (3.3)
Thyroglossal duct 1 (1.0) 0 (0.0) 0 (0.0) 1 (1.6)
Unknown 6 (5.7) 1 (10.0) 2 (5.9) 3 (4.9)
Multifocality, no. (%)
No 50 (47.6) 4 (40.0) 18 (52.9) 28 (45.9) 0.632
Yes 29 (27.6) 3 (30.0) 7 (20.6) 19 (31.1)
Unknown 26 (24.8) 3 (30.0) 9 (26.5) 14 (23.0)
TNM stage, no. (%)
T
T1-T2 65 (61.9) 6 (60.0) 21 (61.8) 38 (62.3) 0.960
T3-T4 26 (24.8) 2 (20.0) 9 (26.5) 15 (24.6)
Tx 14 (13.3) 2 (20.0) 4 (11.8) 8 (13.1)
N
N0 53 (50.5) 4 (40.0) 15 (44.1) 34 (55.7) 0.339
N1a-N1b 46 (43.8) 6 (60.0) 17 (50.0) 23 (37.7)
Nx 6 (5.7) 0 (0.0) 2 (5.9) 4 (6.6)
M
M0 82 (78.1) 8 (80.0) 25 (73.5) 49 (80.3) 0.752
M1b 14 (13.3) 1 (10.0) 6 (17.6) 7 (11.5)
Lung 11 1 5 5
Bone 1 0 0 1
Lung and bone 2 0 1 1
Mx 9 (8.6) 1 (10.0) 3 (8.8) 5 (8.2)
Surgery, no. (%)
Total thyroidectomy 105 (100) 10 (100) 34 (100) 61 (100) -
Lymph node dissection
None 49 (46.7) 4 (40.0) 15 (44.1) 30 (49.2) 0.045
Central LND 10 (9.5) 4 (40.0) 1 (2.9) 5 (8.2)
LND incl. lateral levels 36 (34.3) 2 (20.0) 15 (44.1) 19 (31.1)
Unknown 10 (9.5) 0 (0.0) 3 (8.8) 7 (11.5)
Abbreviation: LND, lymph node dissection. a Differences tested between the 3 age groups. Missing or unknown values excluded from statistical
testing. b Summarized as 1 variable for statistical testing.
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roidectomy, or lymph node dissection,when performed at
different dates) per hospital was 2 (range 1–30). Over the
past decade, 50 patients were treated in 16 different hos-
pitals, including 9 UMCs and 7 general hospitals.
Surgical complications
As shown in Table 2, postoperative transient and per-
manenthypoparathyroidismwereobserved in16 (15.2%)
and 25 (23.8%) patients, respectively. Both transient and
permanent hypoparathyroidism occurred more often in
patients who underwent a lymph node dissection. Unilat-
eral RLN injury occurred in 12 (11.4%) patients. Bilateral
RLN injury occurred only in a 15-year-old patient with
extended disease who was treated with a total thyroidec-
tomy, a central compartment dissection and a bilateral
modified lymph node dissection. The right RLN was en-
casedby the tumor andwas removed as part of the surgical
procedure. RLN injury occurred more often in patients
with tumors staged T3-T4 compared to stage T1-T2 (P
.001), and in patients with lymph node involvement (P
.001). The frequency of surgical complications did not
differ between initial surgery performed before or during
the last decade, either in a crudemodel or after adjustment
for T-stage and performance of lymph node dissection
(OR 0.96, 95% CI 0.42 to 2.17, P  .912 and OR 0.94,
95%CI 0.32 to 2.72, P .904, respectively). Finally, age
group was not related to the occurrence of surgical com-
plications, either in a crude or adjusted model (P  .550
and P  .189, respectively).
131-I administrations and TSH suppressive therapy
Data regarding 131-I administrations are provided in
Table 3. One hundred and two (97.1%) patients were
treated with 131-I, with a median cumulative activity ad-
ministered during initial treatment and follow-up of 5.66
(range 0.74–35.15) GBq. The median number of 131-I
administrations was 1 (range 1–6). Ninety-four (89.5%)
patients underwent 131-I ablation therapy within 6
months after initial surgical treatment. By doctor’s choice,
3 patients did not receive 131-I ablation therapy. Higher
tumor stage (T3-T4), lymph node involvement, and dis-
tant metastases were independently associated with a
higher administered cumulative 131-I activity (P  .001)
and with an increase in the number of 131-I administra-
tions (P  .001). The cumulative 131-I activity and the
number of 131-I administrations during initial treatment
and follow-up did not differ between age groups at diag-
nosis (P  .227 and P  .225, respectively, data not
shown). Pulmonary fibrosis was not encountered in the
medical charts. No patients were treated with external
beam radiotherapy, chemotherapy or tyrosine kinase in-
hibitors for DTC. TSH values of 104 (99.0%) patients
were available for analysis. Median TSH level during fol-
low-up was 0.17 (range 0.01–4.74) mU/L. TSH was sup-
pressedbelow0.10mU/Lduring the entire follow-up in36
(34.6%) patients. The TSH level was not associated with
recurrent disease, either in a crude model (OR 1.98, 95%
CI 0.80 to 4.86, P  .140), or after adjustment for risk
classification (OR 2.00, 95% CI 0.78 to 5.17, P .152).
Outcome
At last known follow-up, 9 (8.6%) patients had per-
sistent disease, 6 of whomwere classified as such based on
a detectable Tg level. Eight (7.6%) patients experienced a
recurrence (Table 4). Recurrence free survival (RFS) from
initial treatment to first recurrence ranged from3.9 to22.7
years. Three out of 8 patients relapsed within 5 years after
initial treatment. Of the 11 (10.5%) patients who had not
been treated with 131-I within 6 months after total thy-
roidectomy, 2 developed a recurrence (P .197, data not
shown). As shown in Table 5, T3-T4 stage, lymph node
involvement, and distantmetastases stagewere associated
with persistent disease (P .040, P .010 and P .020,
respectively). No associations were found between initial
TNM stage and recurrences. The 3 patients who initially
presented with bone metastases became free of disease
after administration of 13.7, 11.8 and 14.8 GBq 131-I,
and remained in remissionafter a follow-upof2.9, 5.1 and
13.2 years, respectively. Outcome did not differ between
patients with PTC and FTC, or between the 3 age groups
(P  .411 and P  .789, respectively, data not shown).
Table 2. Surgical complications
Hypoparathyroidism, no. (%) Recurrent laryngeal nerve injury, no. (%)
Group None Transient Permanent Unknown None Left Right Bilateral Unknown
All patients
(n  105)
51 (48.6) 16 (15.2) 25 (23.8) 13 (12.4) 69 (65.7) 5 (4.8) 7 (6.7) 1 (1.0) 23 (21.9)
T1-T2 (n  65) 36 (55.4) 8 (12.3) 14 (21.5) * 7 (10.8) 52 (80.0) 1 (1.5) 0 (0.0) 0 (0.0) *** 12 (18.5)
T3-T4 (n  26) 10 (38.5) 7 (26.9) 8 (30.8) 1 (3.8) 14 (53.8) 2 (7.7) 4 (15.4) 1 (3.8) 5 (19.2)
Tx (n  14) 5 (35.7) 1 (7.1) 3 (21.4) 5 (35.7) 3 (21.4) 2 (14.3) 3 (21.4) 0 (0.0) 6 (42.9)
No LND
(n  49)
32 (65.3) 6 (12.2) 5 (10.2) ** 6 (12.2) 39 (79.6) 0 (0.0) 0 (0.0) 0 (0.0) *** 10 (20.4)
LND (n  46) 15 (32.6) 10 (21.7) 16 (34.8) 5 (10.9) 28 (60.9) 4 (8.7) 6 (13.0) 1 (2.2) 7 (15.2)
LND unknown
(n  10)
4 (40.0) 0 (0.0) 4 (40.0) 2 (20.0) 2 (20.0) 1 (10.0) 1 (10.0) 0 (0.0) 6 (60.0)
Abbreviation: LND, lymph node dissection. Differences tested between T1-T2 and T3-T4 and no LND and LND (see shaded numbers). Missing or
unknown values excluded from statistical testing. *P  0.143, **P  0.001, ***P  0.001.
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Outcome could not be assessed for 2 patients because of
follow-up  1 year. For another patient, information to
evaluate outcome was not available.
Median follow-up in patients with recurrent disease
was 24.7 (10.7–41.5) years, significantly longer than in
patients who remained in remission (11.4 (1.3–44.7)
years) and in patients with persistent disease (5.5 (1.7–
36.1) years) (P  .030, data not shown).
Data regarding SMNsafter pediatricDTCareprovided
in Supplemental Table 3.
Discussion
This nationwide study of pediatric patients with well-dif-
ferentiated thyroid cancer in the Netherlands confirms an
excellent overall survival. All patients underwent total
thyroidectomy with nodal dissection in 43.8%, followed
inmostpatientsbyhigh-dose131-I ablation therapy.Over
a43-yearperiod, 105patientswere surgically treated in39
hospitals. In 32.4% of them lifelong postoperative com-
plications (permanent hypoparathyroidism and/or RLN
injury) were present. A significant number of patients had
persistent disease or experienced a recurrence. Despite
small patient numbers, our cohort is one of the largest to
bedescribed for this raredisease in children. It gives insight
into relevant clinical parameters that can be used to im-
prove evidence-based treatment and follow-up strategies.
In our opinion, the incidence of hypoparathyroidism,
using strict definitions in our cohort, seems to be relatively
high compared to comparable cohorts of pediatric pa-
Table 3. 131-I administrations
Group
Cumulative 131-I activity
(GBq)
P
valueb
I-131
administrations,
no.
P
valueb
All patients (n 
100)a
5.66 (0.74–35.15) 1 (1–6)
T1-T2 (n  62) 5.55 (0.74–31.49) 0.001 1 (1–6) 0.001
T3-T4 (n  26) 12.36 (1.78–35.15) 3 (1–6)
Tx (n  12) 4.63 (1.22–27.85) 1 (1–5)
N0 (n  49) 3.70 (1.00–21.46) 0.001 1 (1–6) 0.001
N1a-N1b (n  45) 11.10 (0.74–35.15) 2 (1–6)
Nx (n  6) 6.75 (1.85–8.33) 1 (1–2)
M0 (n  77) 5.55 (0.74–35.15) 0.001 1 (1–6) 0.001
M1 (n  14) 14.43 (6.11–29.79) 3 (1–5)
Mx (n  9) 5.55 (1.85–27.85) 1 (1–5)
All data expressed as median (range). a Administered 131-I activity unknown in 2 patients; 3 patients did not receive 131-I treatment. Therefore
n  100 instead of n  105. b Differences tested between T1-T2 and T3-T4, N0 and N1a-N1b, M0 and M1. Tx, Nx, Mx excluded from statistical
testing.
Table 4. Patients with recurrent and persistent disease
Sex and age at diagnosis, years
Follow-up,
years Histology, TNMa
Initial
treatmentb Evidence of disease
Localization of
recurrence
RFS
c, years
Remission after
recurrence
2nd
recurrence Remission after 2nd recurrence
Recurrent disease (n  8)
F, 18.9 33.3 PTC, T2N0M0 TT  131-I Scintigraphical Thyroid bed 3.92 yes no n.a.
F, 18.3 10.7 PTC, T1bN0M0 TT  131-I Scintigraphical Cervical LN 4.16 yes no n.a.
F, 17.1 17.5 PTC, T3N1bM0 TT  131-I Cytological Cervical LN 4.81 yes yes yes
F, 13.3 41.5 FTC, T4aN1bM0 TT  131-Id Scintigraphical Cervical LN 6.15 yes yes no
F, 16.3 12.0 PTC, T2N0M0 TT  131-I Scintigraphical Cervical LN 8.96 yes no n.a.
F, 13.1 32.4 PTC, T1bN1bM0 TT  LND  131-I Biochemicale Not specified 11.04 yes no n.a.
F, 13.1 25.2 PTC, T1bN1bM0 TT  LND Histological Cervical LN 16.62 yes no n.a.
F, 18.8 24.3 PTC, T1bN0Mx TT Histological 
radiologicalf
Cervical LN, lung 22.65 no n.a. n.a.
Persistent disease (n  9)
F, 12.5 23.3 PTC, T2N1M0 TT  LND  131-I Radiological Lung
M, 10.5 8.4 PTC, T4aN1bM1 TT  LND  131-I Radiological Lung
F, 18.5 1.7 PTC, T4bN1bM1 TT  LND  131-I Scintigraphical 
radiologicalg
Cervical LN, lung
F, 12.1 4.9 PTC, T2N1bM0 TT  LND  131-I Biochemical Not specified
F, 16.1 5.5 PTC, T1N1bM0 TT  LND  131-I Biochemical Not specified
M, 12.7 14.8 PTC, T3N1bM0 TT  LND  131-I Biochemical Not specified
M, 14.7 4.4 PTC, T3N0M1 TT  131-I Biochemical Not specified
F, 15.9 2.0 PTC, T4aN1bM1 TT  LND  131-I Biochemical Not specified
F, 16.7 36.1 PTC, TxN1bMx TT  LND  131-I Biochemical Not specified
Abbreviations: F, female; M, male; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; TT, total thyroidectomy; LND, lymph node
dissection; 131-I, radioiodine administration; LN, lymph node; RFS, recurrence-free survival; n.a., not applicable. a Initial TNM classification, b 131-I
is mentioned as part of initial therapy if performed 6 months after surgical treatment, c RFS calculated from date of diagnosis until first
recurrence, d Unknown if LND was performed; e Patient treated with 131-I because of increasing thyroglobulin level. Unknown if post therapy scan
was performed; f Cervical lymph nodes proved histologically. Lung metastases visible on CT; g Cervical lymph nodes detected scintigraphically. Lung
metastases visible on CT.
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tients treated for DTC (transient and permanent hypo-
parathyroidism in 15.2% and 23.8%, respectively, previ-
ously described in 7.4–32.7% and 0%–32%,
respectively) (12, 20–23). In adults, these complications
were less frequently encountered (6.2–14.2% and
0–4.0%, respectively) (24, 25). The occurrence of RLN
injury in our cohort (12.4%) was comparable with other
pediatric cohorts (0%–40%), as well as with reported
adult data (0–38.4%) (14, 21, 26, 27).However, it should
be considered that definitions of surgical complications
are heterogeneous. Complication rates therefore vary
widely in the literature. Total thyroidectomy, which is
recommended for the vast majority of pediatric patients
with DTC, is associated with a higher complication risk
than partial thyroidectomy, particularly when combined
with lymph node dissection (4–6, 13). Anothermajor fac-
tor that could have contributed to our complication rates
might be the high number of centers where surgery was
performed on this low volume high-risk patient group.
Due to the lownumbers of surgical treatments per hospital
in our cohortwewere not able to analyze differences in the
occurrence of surgical complications between high- and
low-volume centers. However, it has been shown that
complications of thyroid surgery in pediatric patients are
reduced when surgery is performed by high-volume sur-
geons (6). High-volume surgery may also be associated
with fewer incomplete resections. Therefore the need for
further centralization of care for pediatric patients with
DTC is essential, as has been recommended by the ATA
(4).
The cumulative therapeutic 131-I activity during initial
treatment and follow-up in our cohortwas relatively high.
Given the good survival rate, it can be questionedwhether
children could just as well be treated with lower thera-
peutic activities, as suggested by recent guidelines (4, 5).
The dosage of 131-I is of importance, given that pulmo-
nary fibrosis was observed as a side effect in 7.2% of pa-
tients with lung metastases in a high-risk Chernobyl-re-
lated pediatric cohort (28). In our cohort we did not
observe pulmonary fibrosis after a similar follow-up pe-
riod. As the presence of pulmonary fibrosis was assessed
from medical records in our study, we may have missed
subclinical cases. Nevertheless, it is our opinion that the
administration of 131-I should be considered very care-
fully in pediatric patients to prevent possible early and late
adverse effects (29, 30). This is especially the case in chil-
dren with low-risk DTC as no benefit of 131-I ablation
therapy has been shown in adults with low-risk disease
(31). High 131-I activities should be reserved for children
withmetastatic disease, as advocated earlier byVerburg et
al (7).
In about one-third of the patients in our cohort TSH
was suppressed during the entire follow-up. To the best of
our knowledge, our study is the first to report that TSH
level is not associated with recurrent disease in children
with DTC. This finding upholds the first ATA guidelines
for pediatric patients with DTC, which recommend tem-
pering TSH suppression in children showing no evidence
of disease (4). However, this should be interpreted care-
fully as our study probably has a lack of power.
The prevalence of cervical lymph node metastases at
initial diagnosis in our cohort (43.8%) is in the lower
range of prevalences as reported in other pediatric series
(39%–90%) (15, 21, 22, 32–34). The prevalence of dis-
tant metastases in our study is comparable to that from
other pediatric cohorts (32, 33).
Persistent diseasewasmoreoften found inpatientswith
higher T stage, cervical lymph node involvement and dis-
tant metastases at diagnosis. One-third of the patients
with persistent disease had lung metastases at last known
Table 5. Outcome
Group
Remission, no.
(%)
Recurrence,
no. (%)
P
valuea,b
Persistent
disease, no.
(%)
P
valuea,c
Unknown,
no. (%)d
All patients (n 
105)
85 (81.0) 8 (7.6) 9 (8.6) 3 (2.9)
T1-T2 (n  65) 54 (83.1) 6 (9.2) 1.000 3 (4.6) 0.040 2 (3.1)
T3-T4 (n  26) 18 (69.2) 2 (7.7) 5 (19.2) 1 (3.8)
Tx (n  14) 13 (92.9) 0 (0.0) 1 (7.1) 0 (0.0)
N0 (n  53) 47 (88.7) 4 (7.5) 0.713 1 (1.9) 0.010 1 (1.9)
N1a-N1b (n  46) 32 (69.6) 4 (8.7) 8 (17.4) 2 (4.3)
Nx (n  6) 6 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
M0 (n  82) 70 (85.4) 7 (8.5) 1.000 4 (4.9) 0.020 1 (1.2)
M1 (n  14) 10 (71.4) 0 (0.0) 4 (28.6) 0 (0.0)
Mx (n  9) 5 (55.6) 1 (11.1) 1 (11.1) 2 (22.2)
a Differences tested between T1-T2 and T3-T4, N0 and N1a-N1b, M0 and M1. Tx, Nx, Mx and unknown outcome excluded from statistical testing.
b
Patients in remission and with recurrent disease compared. c Patients in remission and with persistent disease compared. d Outcome unknown in
1 patient and could not be assessed in 2 patients due to follow-up 1 yr (all summarized as unknown outcome).
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follow-up. The other two-thirds were classified as having
persistent disease based on a detectable Tg level. Itmust be
considered that Tg levels are not always analyzed in the
literature, and that patients with detectable Tg levels are
not always classified as having persistent disease in other
studies.
We report a recurrence rate of 7.6%,which is low com-
pared with a study involving comparable treatment and
follow-up (18.8%) (33). Our study definitions of recur-
rent disease may have contributed to the low recurrence
rate, as we did not interpret disease activity within 1 year
after initial treatment as recurrent disease. In contrast to
some other studies, in our cohort recurrences were not
associated with initial TNM stage and did not differ be-
tween age groups (14, 33, 35). RFS ranged from 3.9–22.7
years. This favors lifelong follow-up of children. Patients
with recurrent disease were significantly longer in fol-
low-up compared to patients in remission and with per-
sistent disease. This prolonged follow-up might be ex-
plained by the wish of physicians to follow patients with
recurrent disease for a longer time than patients who re-
main in remission.
Possible differences in presentation of sporadic DTC
compared to radiation-induced DTC could not be de-
tected, as the number of patients with SMN in our cohort
was low and the median follow-up was relatively short to
develop a SMN.
Limitations of this study are related to its retrospective
design. As patients were treated in many hospitals over
more than 40 years, complete information from medical
records could not always be retrieved. Furthermore, pre-
operative staging and patient management were not sim-
ilar inall hospitals andhave evolvedover time. Inaddition,
the association between lymph node dissection and oc-
currence of surgical complications should be interpreted
carefully as the number of procedures per hospital was
small and information on the selection criteria for the ex-
tent of surgery was often lacking. However, over the last
decades the general consensus on treatment for pediatric
DTC has in the Netherlands remained roughly un-
changed. Finally, various TSH assays have been used.
However, we expect limited influence of the assay differ-
ences on the results, as the lower limits of the reference
ranges remained more or less stable.
In conclusion, the life expectancy for children with
DTC is excellent. However, many patients experience ad-
verse effects from thyroid surgery, resulting in lifelong
complications in 32.4%. Centralization of care for pedi-
atric patients with DTC is crucial to reduce treatment-
related damage in this young patient group. In the near
future, treatment for pediatric patients with DTC will be
further centralized in one or two hospitals in The Neth-
erlands. Furthermore, the administration of 131-I should
beweighed very carefully to prevent early and late adverse
events. Further studies are needed to evaluate long-term
sequels. International collaboration using homogeneous
definitions can accelerate evaluation and improvement of
treatment for children with DTC.
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Supplemental Table 1. Participants versus non-participants 
Variable Participants (n = 105) Non-participants (n = 64) P valuea 
Sex, no. (%)         
 Male 17  (16.2)  19  (29.7)  
0.038  
 Female 88  (83.8)  45  (70.3)  
Age at diagnosis, yearsb         
 Median (range) 15.6  (5.8-18.9)  15.5  (4.9-18.8)  0.498  
Histology, no. (%)         
 Papillary 85  (81.0)  50  (78.1)  
0.394  
 Follicular 20  (19.0)  8  (12.5)  
 Unknown 0  (0.0)  6  (9.4)    
TNM stage, no. (%)         
 T         
  T1-T2 65  (61.9)  21  (32.8)  
0.217  
  T3-T4 26  (24.8)  14  (21.9)  
  Tx 14  (13.3)  29  (45.3)    
 N         
  N0 53  (50.5)  17  (26.6)  
0.194  
  N1a-N1b 46  (43.8)  24  (37.5)  
  Nx 6  (5.7)  23  (35.9)    
 M         
  M0 82  (78.1)  27  (42.2)   
0.031  
  M1 14  (13.3)  12  (18.8)  
  Mx 9  (8.6)  25  (39.1)    
Follow-up, years          
 Median (range) 11.7  (1.1-44.7)  18.1  (0.3-40.4)b  0.043  
a Missing or unknown values and Tx, Nx, Mx excluded from statistical testing. b If date of diagnosis was available 
(n = 61). 
Supplemental Table 2. History of radiotherapy and malignant neoplasms during childhood 
Variable Patients (n = 105) 
Age at diagnosis 
primary malignancy 
other than DTC 
Age at 
diagnosis 
DTC 
Histology and 
TNM DTC 
DTC as primary malignancy, no. (%)     
 No history of radiation 99 (94.3) - - - 
 History of cervical radiation for benign conditionsa 2 (1.9) - 17 y; 16 y 
PTC, TxN1bM0;  
PTC, T1bN0M0 
DTC as Second Malignant 
Neoplasm, no. (%)     
 Langerhans cell histiocytosis 1 (0.95) 8 y 18 y FTC, T2N0M0 
  Chemob     
 Acute Lymphoblastic Leukemia  1 (0.95) 5 y 10 y PTC T1bN0M0 
  Chemo + RTc     
 Medulloblastoma 1 (0.95) 9 y 18 y PTC, T3N1bM1 
  Chemo + RTd     
 Neuroblastoma 1 (0.95) 4 m 6 y PTC, T1N1M0 
  131-I-MIBG + chemoe     
Abbreviations: DTC, differentiated thyroid carcinoma; Chemo, chemotherapy; RT, radiotherapy; 131-I-MIBG, 
131-I-metaiodobenzylguanidine; y, years; PTC, papillary thryoid carcinoma; FTC, follicular thyroid carcinoma. 
a One patient received cervical RT for eczema (total dose 7.2 Gy) between ages 4-17 years. The second patient 
received cervical RT (total dose breast and cervical region 32 Gy between ages 1-12 months for a nevus 
flammeus. Patients received RT between 1958 and 1970. b Vinblastine, prednisolone, 
cyclophosphamide. c Rubidomycin, adriamycin, cyclophosphamide + cranial RT dose 18 Gy. d Vincristine, 
cysplatinum + craniospinal RT dose 23.4 Gy. e 4x 131-I-MIBG + carboplatin, vincristine, etoposide, carboplatin, 
ifosfamide (VECI). 
Supplemental Table 3. Second malignant neoplasms after pediatric differentiated thyroid carcinoma 
Sex Histology and TNM 
Age at 
diagnosis DTC, 
years 
Cumulative 131-I 
activity (GBq) before 
SMN 
SMN 
Age at 
diagnosis SMN, 
years 
F PTC, TxNxMx 11 8.33 Breast cancer 39 
F FTC, T4aN1bM0 13 35.15
a  Breast cancer 53 
F PTC, T1bN1bM0 13 0 
High-grade cervical 
intraepithelial 
neoplasia 
26 
Abbreviations: DTC, differentiated thyroid carcinoma; SMN, second malignant neoplasm; F, female; PTC, 
papillary thyroid carcinoma; FTC, follicular thyroid carcinoma. a During follow-up, this patient developed 2 
recurrences, for which she was treated with 131-I.   
